701906-29-8

Basic information

• Product Name: 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid
• CAS NO: 701906-29-8
• Molecular Weight: 445.602
• Mol File: 701906-29-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid(701906-29-8)
• EPA Substance Registry System: 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoic acid(701906-29-8)

Safety Data

• Hazardous Substances Data: 701906-29-8(Hazardous Substances Data)

Upstream product

• 865889-33-4 R-(-)3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 
• 1429299-07-9 (3R)-3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoyl chloride 
• 1429299-08-0 R-(-)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionamide 
• 100-44-7 benzyl chloride 
• 1185739-54-1 (+/-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid 
• 1429299-06-8 R-(-)-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid (1S,2R)-ephedrine salt 
• 621-82-9 Cinnamic acid 
• 1135493-18-3 C₂₀H₁₈O₈*C₂₈H₃₄BrNO 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 106-41-2 4-bromo-phenol 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 124-38-9 carbon dioxide 

Downstream Products

• 250214-39-2 (-)-N,N-diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

The present invention relates to a process for the preparation of fesoterodine or its salts.

IMPROVED PROCESS FOR DIPHENYLPROPYLAMINE DERIVATIVES

The present invention relates to an improved process for the preparation of biologically active diphenylpropylamine derivatives. The present invention specifically relates to an improved fesoterodine of formula (I) and its pharmaceutically acceptable salts.